Table 1. Growth Inhibition IC50 Values of Synthetic Pyridine-Bridged CA-4 Analogues in Three Cancer Cell Lines: MDA-MB-231, A549, and HeLa.
| growth inhibition IC50 (μM) |
|||
|---|---|---|---|
| combretastatin analogues | MDA-MB-231 | A549 | HeLa |
| 2a | 6.0 ± 3.5 | 9.0 ± 0.1 | 12.0 ± 0.2 |
| 2b | >25 | >25 | >50 |
| 2c | >100 | >50 | >50 |
| 2d | 10.0 ± 0.1 | 2.0 ± 0.2 | 2.0 ± 0 |
| 2e | 12.05 ± 0.02 | >25 | 14.0 ± 0.3 |
| 2f | >100 | >100 | >25 |
| 3a | 11.0 ± 1.8 | >50 | 1.0 ± 0.2 |
| 3b | >50 | >50 | >25 |
| 3c | 0.075 ± 0.001 | 0.079 ± 0.019 | 0.011 ± 0.001 |
| 3d | 9.0 ± 1.0 | >100 | 2.0 ± 0.4 |
| 3e | 11.0 ± 0.4 | >100 | 2.68 ± 0.08 |
| 3f | 2.63 ± 0.15 | 7.86 ± 0.233 | 0.79 ± 0.02 |
| 3g | >100 | >100 | >50 |
| 3h | >50 | >50 | >25 |
| 4a | 10.00 ± 1.56 | >25 | 8.0 ± 0.5 |
| 4b | >50 | >100 | 0.86 ± 0.01 |
| 4c | 2.49 ± 0.0022 | >50 | 0.026 ± 0.001 |
| 4d | >25 | >25 | >25 |
| 4e | 13.0 ± 0.1 | >25 | >50 |
| 4f | >25 | >50 | >50 |
| 4g | >100 | 0.69 ± 0.05 | 4.43 ± 0.08 |
| 4h | 0.0031 ± 0.0003 | 0.089 ± 0.008 | 0.0038 ± 0.0001 |
| 4i | >50 | >50 | >25 |
| 4j | >25 | >25 | >50 |
| 4k | 17.2 ± 2.6 | 4.22 ± 0.58 | >100 |
| 4l | >25 | >25 | >50 |
| 4m | 0.034 ± 0.004 | 0.33 ± 0.01 | 0.034 ± 0.002 |
| 4n | >50 | >50 | >50 |
| 4o | >100 | >100 | >50 |
| 4p | 9.02 ± 0.09 | 0.56 ± 0.01 | 0.067 ± 0.007 |
| 4q | >50 | >50 | >25 |
| 4r | >25 | >50 | >25 |
| 4s | 0.0046 ± 0.0001 | 0.044 ± 0.002 | 0.0014 ± 0.0003 |
| 4t | 0.069 ± 0.0028 | 2.64 ± 0.38 | 0.0047 ± 0.0009 |
| 5 | 0.0054 ± 0.0006 | 0.042 ± 0.008 | 0.0026 ± 0.0006 |
| CA-4 | 0.0028 ± 0.0004 | 0.0038 ± 0.0003 | 0.0009 ± 0.0003 |